A Phase III, multicenter, randomized, open‑label clinical study comparing Zanzalintinib with Everolimus in patients with locally advanced or metastatic neuroendocrine tumors (NETs).

👥 Eligibility Criteria

  • Previously treated, unresectable locally advanced or metastatic epNET or pNET (well‑differentiated, G1–3)

  • Functional epNET: ≤1 prior line of therapy

  • Non‑functional NET: ≤1 prior line of therapy (excluding SSAs)

  • No prior VEGFR‑TKI or mTOR inhibitor treatment

  • Disease progression within the past 12 months per RECIST 1.1

💊 Study Design

1:1 Randomization

  • Arm A: Zanzalintinib

  • Arm B: Everolimus (with optional crossover to Zanzalintinib) 👉 Treatment continues until loss of clinical benefit, unacceptable toxicity, or need for subsequent systemic anticancer therapy

🎯 Study Endpoints

  • Disease control and survival outcomes

  • Safety and tolerability

  • Patient‑reported outcomes (PROs)

🎁 Participant Benefits

  • Free study medication, imaging scans, and physician consultations

  • Transportation allowance for each study visit

  • Continuous follow‑up by a professional medical team

⚠️ Potential Risks

You may experience discomfort or side effects during treatment, which vary from person to person. The study doctors will provide ongoing monitoring and professional support.

Personal Data Disclosure Disclaimer: We may collect, use, and disclose your personal data in accordance with the Personal Data (Privacy) Ordinance. Your information will be handled with care and only used for the purposes specified at the time of collection.